Drug
Kk2223
Kk2223: highest development phase Phase 1, developed by Kyowa Kirin. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Kyowa Kirin
Trials
| Drug | Phase | Indication |
|---|---|---|
| KK2223 NCT07192471 | Phase 1 | T-cell NHL (PTCL or CTCL) |
Latest
No recent events.
Follow Kk2223 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.